Search

Your search keyword '"Sarobba, Mg"' showing total 3 results
Start Over Author "Sarobba, Mg" Topic anthracyclines
3 results on '"Sarobba, Mg"'

1. Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines.

Author

Berruti A, Bitossi R, Gorzegno G, Bottini A, Generali D, Milani M, Katsaros D, Rigault de la Longrais IA, Bellino R, Donadio M, Ardine M, Bertetto O, Danese S, Sarobba MG, Farris A, Lorusso V, and Dogliotti L

Subjects
Adult, Aged, Antimetabolites, Antineoplastic administration & dosage, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Drug Administration Schedule, Female, Fluorouracil administration & dosage, Humans, Infusions, Intravenous, Middle Aged, Paclitaxel administration & dosage, Survival Analysis, Treatment Outcome, Vinblastine administration & dosage, Vinorelbine, Anthracyclines administration & dosage, Antibiotics, Antineoplastic administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Vinblastine analogs & derivatives
Abstract

We investigated the activity and toxicity of a combination of vinorelbine (VNB), paclitaxel (PTX) and 5-fluorouracil (5-FU) continuous infusion administered as first-line chemotherapy in metastatic breast cancer patients pretreated with adjuvant anthracyclines. A total of 61 patients received a regimen consisting of VNB 25 mg m(-2) on days 1 and 15, PTX 60 mg m(-2) on days 1, 8 and 15 and continuous infusion of 5-FU at 200 mg m(-2) every day. Cycles were repeated every 28 days. Disease response was evaluated by both RECIST and World Health Organization (WHO) criteria. Objective responses were recorded in 39 of 61 patients (64.0%) assessed by WHO and in 36 of 50 patients (72.0%) assessable by RECIST criteria. Complete remission occurred in 15 (24.6%) and 14 patients (28.0%), respectively. The median time to progression and overall survival of entire population was 10.6 and 27.3 months, respectively, and median duration of complete response was 14.8 months. The dose-limiting toxicity was myelosuppression (leucopenia grade 3/4 in 52.5% of patients). Grade 3/4 nonhaematologic toxicities included mucositis/diarrhoea in 13.1%, skin in 3.3% and cardiac in 1.6% of patients. Grade 2/3 neurotoxicity was observed in five patients (7.2%). The VNB, PTX and 5-FU continuous infusion combination regimen was active and manageable. Complete responses were frequent and durable.

Published
2005
Full Text
View/download PDF

2. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

Author

Silvano Palazzo, G Pistillucci, Sergio Palmeri, Rossella Lauria, Vincenzo Adamo, Vito Lorusso, G. Petrella, S. De Placido, C. Pagliarulo, L. Manzione, M. De Lena, M. De Laurentiis, A. Paradiso, M. D'Aprile, Maria Giuseppa Sarobba, Gennaro Limite, Antonio Farris, F. Ferraù, R. Costanzo, Ar Bianco, DE PLACIDO S, DE LAURENTIIS M, DE LENA M, LORUSSO V, PARADISO A, DAPRILE M, PISTILLUCCI G, FARRIS A, SAROBBA MG, PALAZZO S, MANZIONE L, ADAMO V, PALMERI S, FERRAU F, LAURIA R, PAGLIARULO C, PETRELLA G, LIMITE G, COSTANZO R, and BIANCO AR

Subjects
Adult, Cancer Research, medicine.medical_specialty, Cyclophosphamide, medicine.medical_treatment, Urology, Breast Neoplasms, Disease-Free Survival, Drug Administration Schedule, breast cancer, chemoendocrine treatment, Antineoplastic Combined Chemotherapy Protocols, Clinical Studies, medicine, Adjuvant therapy, Humans, Doxorubicin, anthracyclines, Gynecology, Chemotherapy, premenopausal, business.industry, Goserelin, adjuvant therapy, Middle Aged, Combined Modality Therapy, Tamoxifen, Regimen, Methotrexate, Oncology, Chemotherapy, Adjuvant, Fluorouracil, Lymphatic Metastasis, Female, business, Follow-Up Studies, medicine.drug
Abstract

The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A × CMF or arms a + c vs b + d) and (2) the effect of adding GT after chemotherapy (arms a + b vs c + d). At a median follow-up of 72 months, A → CMF as compared to CMF significantly improved disease-free survival (DFS) with a multivariate hazard ratio (HR) = 0.740 (95% confidence interval (CI): 0.556-0.986; P = 0.040) and produced a nonsignificant improvement of overall survival (OS) (HR = 0.764; 95% CI: 0.489-1.193). The addition of GT after chemotherapy significantly improved DFS (HR = 0.74; 95% CI: 0.555-0.987; P = 0.040), with a nonsignificant improvement of OS (HR = 0.84; 95% CI: 0.54-1.32). A → CMF is superior to CMF. Adding GT after chemotherapy is beneficial for premenopausal node-positive patients. © 2005 Cancer Research UK.

Published
2005
Full Text
View/download PDF

3. Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines

Author

Manuela Milani, Gabriella Gorzegno, Alfredo Berruti, Raffaella Bitossi, Luigi Dogliotti, Alberto Bottini, I. A. Rigault de la Longrais, Vito Lorusso, Dionyssios Katsaros, S. Danese, Mara Ardine, Oscar Bertetto, Maria Giuseppa Sarobba, Daniele Generali, Michela Donadio, Antonio Farris, R. Bellino, Berruti, A, Bitossi, R, Gorzegno, G, Bottini, A, Generali, D, Milani, M, Katsaros, D, de la Longrais, Iar, Bellino, R, Donadio, M, Ardine, M, Bertetto, O, Danese, S, Sarobba, Mg, Farris, A, Lorusso, V, Dogliotti, L, Berruti, A., Bitossi, R., Gorzegno, G., Bottini, A., Generali, D., Milani, M., Katsaros, D., Rigault De La Longrais, I. A., Bellino, R., Donadio, M., Ardine, M., Bertetto, O., Danese, S., Sarobba, M. G., Farris, A., Lorusso, V., and Dogliotti, L.

Subjects
Adult, Cancer Research, medicine.medical_specialty, Antimetabolites, Antineoplastic, Paclitaxel, medicine.drug_class, medicine.medical_treatment, Breast Neoplasms, Vinorelbine, Vinblastine, Gastroenterology, Antimetabolite, Disease-Free Survival, Drug Administration Schedule, paclitaxel, Breast cancer, breast cancer, metastatic disease, vinorelbine, 5-fluorouracil, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Clinical Studies, Mucositis, Medicine, Humans, Anthracyclines, Infusions, Intravenous, Aged, Chemotherapy, Antibiotics, Antineoplastic, business.industry, Middle Aged, medicine.disease, Metastatic breast cancer, Antineoplastic Agents, Phytogenic, Survival Analysis, Surgery, Regimen, Treatment Outcome, Oncology, Fluorouracil, Female, business, medicine.drug
Abstract

We investigated the activity and toxicity of a combination of vinorelbine (VNB), paclitaxel (PTX) and 5-fluorouracil (5-FU) continuous infusion administered as first-line chemotherapy in metastatic breast cancer patients pretreated with adjuvant anthracyclines. A total of 61 patients received a regimen consisting of VNB 25 mg m(-2) on days 1 and 15, PTX 60 mg m(-2) on days 1, 8 and 15 and continuous infusion of 5-FU at 200 mg m(-2) every day. Cycles were repeated every 28 days. Disease response was evaluated by both RECIST and World Health Organization ( WHO) criteria. Objective responses were recorded in 39 of 61 patients (64.0%) assessed by WHO and in 36 of 50 patients (72.0%) assessable by RECIST criteria. Complete remission occurred in 15 (24.6%) and 14 patients (28.0%), respectively. The median time to progression and overall survival of entire population was 10.6 and 27.3 months, respectively, and median duration of complete response was 14.8 months. The dose-limiting toxicity was myelosuppression (leucopenia grade 3/4 in 52.5% of patients). Grade 3/4 nonhaematologic toxicities included mucositis/diarrhoea in 13.1%, skin in 3.3% and cardiac in 1.6% of patients. Grade 2/3 neurotoxicity was observed in five patients (7.2%). The VNB, PTX and 5-FU continuous infusion combination regimen was active and manageable. Complete responses were frequent and durable.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results